Top
Why Prices Drop at Launch: The First Generic Entry Effect
Feb 3, 2026
Posted by Graham Laskett

When a new product hits the market, you’d expect it to be expensive. That’s how it’s always been - early adopters pay more, and prices come down over time. But something different happens with first generic entry. It’s not a slow decline. It’s a crash. Within weeks, sometimes days, prices plunge by half or more. And it’s not just drugs. It’s software, electronics, even cloud services. Why?

It’s Not About Cost - It’s About Control

Think back to when Apple first launched the iPod in 2001. It cost $399. No competition. People bought it because there was nothing else. Then, in 2004, companies like Creative and Sony started making MP3 players. Within two years, you could buy a decent one for under $100. Apple didn’t suddenly become cheaper to make. They didn’t cut corners. The price dropped because the monopoly ended.

That’s what first generic entry does. It breaks control. When a company has no rivals, they set the price. When someone else steps in with a version that works just as well - even if it’s not perfect - everything changes.

In pharmaceuticals, this is well-documented. When a drug’s patent expires, the first generic version hits shelves and prices drop 76% on average within six months, according to the Congressional Budget Office. Why? Because the drug hasn’t changed. The chemistry is identical. But now there are two suppliers. And buyers - pharmacies, insurers, patients - will go with the cheaper one.

Software Follows the Same Script

You might think software is different. It’s not physical. You can’t reverse-engineer it like a pill. But you can copy the function. And that’s exactly what happens.

Take Oracle’s database. For years, enterprises paid tens of thousands in license fees just to run it. Then came PostgreSQL - open source, free to use, and by 2020, it matched 90% of Oracle’s core features. Companies didn’t need every fancy add-on. They needed reliability. Performance. Scalability. PostgreSQL gave them that.

The result? A 78% drop in licensing costs for many, according to user reports on Reddit’s r/sysadmin. One company in Manchester switched from Oracle to PostgreSQL and saved $1.2 million in the first year. They didn’t lose anything. They gained flexibility. And they didn’t need to pay for a vendor’s sales team to keep pushing upgrades.

This isn’t rare. In enterprise software, the first competitive SaaS alternative typically launches at 40-60% below the incumbent’s price. Gartner found that within 18 months, incumbents were forced to cut their license fees by 30-45% just to stay in the game.

Why Do Generic Alternatives Win So Fast?

It’s not just price. It’s timing, perception, and risk.

First, the new entrant doesn’t have legacy costs. No expensive sales force. No decades of R&D to recoup. No shareholders demanding quarterly growth. They’re lean. They’re built on open-source tools like Linux and Apache. Their infrastructure costs are 25-40% lower. That’s where the savings come from.

Second, customers are tired of being locked in. In 2023, 72% of enterprise buyers told Gartner they cared more about total cost of ownership than brand loyalty. If you’re paying $50,000 a year for software and someone offers the same thing for $15,000, you don’t need to be a genius to choose the cheaper option.

Third, the fear of switching has dropped. Early adopters worried about support, integration, training. Now? Most first-gen alternatives offer 24/7 support within 15% of the response time of big vendors. Documentation has improved. Communities have grown. GitHub, Stack Overflow, and Discord are full of people who’ve done the migration before.

A 2023 Pluralsight report found that training for a new system takes 40-60 hours per admin - not trivial, but manageable. And 81% of companies that tried a generic alternative kept it after six months. They didn’t regret it.

Corporate executive shocked by price drop graph while developers celebrate open-source software in 80s anime style.

What Happens to the Original Company?

They don’t disappear. They adapt.

Microsoft saw PostgreSQL and open-source databases eating into Azure SQL’s market share. Instead of fighting it, they shifted to usage-based pricing. Now, you pay only for what you use. That cut their effective price by 35% for mid-sized businesses.

MongoDB didn’t try to beat Oracle on price. They offered a free tier with premium support. That’s not a discount - it’s a strategy. You get in for free. You get comfortable. Then you pay for the features you actually need.

The old model - charge upfront, lock in, upsell later - is dying. The new model is: let them try, prove value, then charge for scale.

It’s Getting Faster - And More Common

Ten years ago, it took 18 months after a patent expired for the first generic to appear. Now? It’s six months. In software, sometimes it’s weeks.

Why? Tools are better. Cloud platforms make deployment easy. AI helps reverse-engineer APIs. Open-source libraries mean you don’t have to build from scratch. The barrier to entry has collapsed.

The European Union’s Digital Markets Act in 2022 forced interoperability standards. That cut switching costs by 40-50%. Now, moving from one system to another doesn’t mean rebuilding your entire IT stack.

Fortune 500 companies now have formal processes to evaluate generic alternatives within three months of their launch. In 2018, only 32% did. Now it’s 67%.

Massive license lock dismantled in server room as customers enter free tiers, neon countdown to 2027 in background.

Is There a Catch?

Yes. But not the one you think.

Some people say generic products are “just a delay tactic.” That’s outdated. Today’s alternatives aren’t half-baked. They’re mature. PostgreSQL runs Netflix. Reddit. Airbnb. They’re not testing the waters - they’re running the show.

The real risk isn’t quality. It’s change fatigue. Migrating systems takes time. Data migration is the biggest headache - 62% of companies outsource it. And if your team is used to one interface, learning a new one feels like starting over.

But the cost of waiting is higher. PTC’s research shows that if you delay your response to a generic competitor by 9-12 months, you lose up to 50% of your projected revenue. That’s not a missed sale. That’s a market collapse.

What Should You Do?

If you’re a buyer: Look for first generic entries. Don’t assume the brand name is better. Check performance benchmarks. Read user reviews on G2 or Capterra. Ask: “What’s the total cost over three years?” Not “What’s the sticker price?”

If you’re a vendor: Stop thinking about protecting your price. Start thinking about protecting your value. Can you offer something the generic can’t? Faster support? Deeper integrations? Custom training? If not, you’re already behind.

The market isn’t broken. It’s working. Competition isn’t a threat - it’s the engine of fairness. Prices drop because customers finally have power. And that’s not going to change.

What’s Next?

ARK Invest predicts open-source alternatives will capture 35% of enterprise software revenue by 2027. That’s not a prediction - it’s an inevitability. The tools are here. The customers are ready. The old rules don’t apply anymore.

The next time you see a product launch with a low price, don’t assume it’s a sale. It might be the start of something bigger. The first generic entry isn’t a footnote. It’s the new normal.

Why do prices drop so fast when a generic product launches?

Prices drop fast because the first generic entry breaks the monopoly. When only one company sells a product, they control the price. Once a competitor offers a similar product - even if it’s not perfect - buyers switch to save money. This forces the original seller to lower prices to stay competitive. In pharmaceuticals, this leads to an average 76% price drop within six months. In software, it’s often 40-60% at launch.

Are generic alternatives as good as the original products?

In most cases, yes. First-gen generics typically match 80-90% of the original’s core functionality. For example, PostgreSQL delivers nearly all the features enterprises need from Oracle databases, at a fraction of the cost. Performance benchmarks show they’re often just as fast and reliable. The main differences are in support depth, documentation, and niche features - not core performance.

Do generic products have poor support?

Not anymore. Early generic products did struggle with support, but today’s market leaders offer 24/7 support with response times within 15% of major vendors. Companies like MongoDB and Red Hat built their business on premium support for open-source tools. Community forums, documentation, and third-party consultants have also filled the gap. Support quality is now a competitive differentiator - not a weakness.

Is switching to a generic product risky?

The biggest risk isn’t the software - it’s the transition. Data migration, staff training, and integration with existing systems can take 3-6 months and require outside help (62% of companies outsource this). But once live, 81% of organizations keep using the alternative. The real danger is waiting too long. Delaying your response to a generic competitor can cost you 50% of your projected revenue, according to PTC.

Why are companies moving away from license-based pricing?

Because customers won’t pay for it anymore. License fees were profitable when buyers had no alternatives. Now, with open-source and SaaS options offering the same functionality at 60-80% lower cost, companies are forced to change. Vendors now use usage-based pricing, freemium tiers, and subscription models to stay relevant. It’s not about lowering prices - it’s about aligning cost with value delivered.

Will this trend keep going?

Absolutely. The time between a product’s launch and its first generic competitor has dropped from 18 months in 2010 to just 6 months in 2023. Cloud platforms, open-source tools, and regulatory changes like the EU’s Digital Markets Act are making it easier and cheaper to enter the market. By 2027, open-source alternatives could capture 35% of enterprise software revenue. The era of high-margin, no-competition pricing is over.

Graham Laskett

Author :Graham Laskett

I work as a research pharmacist, focusing on developing new treatments and reviewing current medication protocols. I enjoy explaining complex pharmaceutical concepts to a general audience. Writing is a passion of mine, especially when it comes to health. I aim to help people make informed choices about their wellness.
About

DB Sentences is your trusted online resource for pharmaceuticals, providing up-to-date information on medications, diseases, and supplements. Discover detailed drug data, disease insights, and supplement facts all in one place. Our user-friendly database offers expert-reviewed content, making it easy to find what you need for better health decisions. Stay informed about drug interactions, side effects, and treatment options. DB Sentences is designed for healthcare professionals, students, and anyone seeking reliable medication information. Explore a comprehensive pharmaceutical reference today.